Retatrutide: The Next Major Weight Loss Option?
Weight-loss medications have changed dramatically over the last several years.
First came drugs that primarily targeted the GLP-1 receptor, such as semaglutide. Then came tirzepatide, which targets both GLP-1 and GIP receptors and generally produces greater average weight loss.
Now another medication is approaching the market that may take this one step further.
It is called retatrutide.
Retatrutide is an investigational once-weekly injection developed by Eli Lilly that activates three different hormone receptors at the same time: GLP-1, GIP, and glucagon.
That is why it is sometimes called a triple agonist.
The results so far have been impressive. In Lilly's Phase 3 TRIUMPH-1 trial, adults without diabetes receiving the highest dose lost an average of 28.3% of their body weight over 80 weeks. Among participants with a starting BMI of at least 35 who continued into an extension, average weight loss reached approximately 30.3% at 104 weeks. (Eli Lilly and Company)
Those numbers begin to approach a range historically associated more with metabolic surgery than medication.
However, retatrutide is still investigational. As of September 2026, it is not FDA-approved and is not legally available as a commercially approved medication. Lilly says it plans to submit retatrutide to the FDA in early 2027. (Eli Lilly and Company)
So what exactly makes retatrutide different?
What is retatrutide?
Retatrutide is a synthetic peptide designed to activate three receptors involved in metabolism and appetite:
GLP-1
GIP
Glucagon
Semaglutide primarily activates GLP-1.
Tirzepatide activates GLP-1 and GIP.
Retatrutide adds a third pathway: the glucagon receptor.
That extra pathway may help explain why the weight-loss results have been so substantial.
What does GLP-1 do?
GLP-1 is a hormone released from the intestine after eating.
It helps:
Increase insulin secretion when glucose is elevated
Reduce appetite
Increase feelings of fullness
Slow gastric emptying
Improve glucose control
This is the main pathway targeted by medications such as semaglutide.
For many patients, GLP-1 medications substantially reduce hunger and make it easier to maintain a calorie deficit.
What does GIP do?
GIP is another hormone released after eating.
It also contributes to glucose-dependent insulin secretion and may interact with the brain and fat tissue in ways that affect appetite and metabolism.
Tirzepatide combines GLP-1 and GIP receptor activation, which appears to produce greater average weight loss than GLP-1 activation alone in many patients.
Retatrutide retains both of these pathways.
Then it adds glucagon.
Why add glucagon?
This is where retatrutide becomes particularly interesting.
Most people associate glucagon with raising blood sugar because it signals the liver to release glucose.
That is true.
But glucagon has several other metabolic effects.
Glucagon receptor activation may also:
Increase energy expenditure
Increase fat oxidation
Reduce fat storage in the liver
Influence appetite
Affect overall energy balance
So retatrutide potentially attacks obesity from both sides of the equation.
GLP-1 and GIP help decrease food intake.
Glucagon may help increase energy expenditure and fat utilization.
That combination could partly explain why retatrutide appears to produce greater weight loss than earlier incretin medications.
How much weight loss are we talking about?
The early Phase 2 trial first caught widespread attention.
In that randomized trial of 338 adults with obesity or overweight without diabetes, the highest retatrutide dose produced an average 24.2% reduction in body weight after 48 weeks, compared with 2.1% with placebo. (New England Journal of Medicine)
Approximately:
100% lost at least 5%
93% lost at least 10%
83% lost at least 15%
in the 12-mg group at 48 weeks. (New England Journal of Medicine)
Those results were already among the most impressive ever reported in an obesity medication trial.
Then came Phase 3.
Phase 3 results may be even more impressive
In May 2026, Lilly announced results from the large Phase 3 TRIUMPH-1 trial.
Participants taking the 12-mg dose lost an average of:
28.3% of their body weight at 80 weeks.
That represented an average loss of approximately 70 pounds.
Nearly half of participants at the highest dose achieved at least 30% weight loss. (Eli Lilly and Company)
Among participants with a baseline BMI of 35 or greater who continued treatment for 104 weeks, average weight loss reached approximately:
30.3%. (Eli Lilly and Company)
These are remarkable numbers for a medication.
What about people with diabetes?
Weight loss is usually somewhat lower with obesity medications in people who also have type 2 diabetes.
Even in this population, retatrutide has produced substantial results.
In the Phase 3 TRIUMPH-2 trial, adults with overweight or obesity and type 2 diabetes taking 12 mg lost an average of 20.8% of body weight at 80 weeks, alongside meaningful improvements in A1C. (Eli Lilly and Company)
Separate Phase 3 diabetes data also showed A1C reductions of up to approximately 2 percentage points, along with substantial weight loss. (Eli Lilly and Company)
That suggests retatrutide may eventually become relevant not only for obesity but also for the broader treatment of metabolic disease.
What about fatty liver disease?
Retatrutide may also have important effects on liver fat.
This is especially interesting because metabolic dysfunction-associated steatotic liver disease, or MASLD, is closely connected to obesity, insulin resistance, and type 2 diabetes.
Earlier studies showed dramatic reductions in liver fat with retatrutide.
This may partly relate to:
Weight loss
Improved insulin sensitivity
Increased fat oxidation
Glucagon receptor activity
Lilly continues to study retatrutide specifically for metabolic liver disease. (Lilly)
Whether this translates into long-term reductions in cirrhosis, liver failure, or liver-related mortality will require much longer studies.
Obstructive sleep apnea and joint disease
The potential benefits may extend beyond the number on the scale.
Obesity contributes substantially to:
Obstructive sleep apnea
Knee osteoarthritis
Cardiovascular disease
Type 2 diabetes
Fatty liver disease
Kidney disease
In Phase 3 studies reported in 2026, retatrutide substantially improved both knee osteoarthritis pain and the severity of moderate-to-severe obstructive sleep apnea in people with obesity. (Eli Lilly and Company)
Some of those benefits are likely mediated by substantial weight reduction itself.
This is an important point.
The real goal of obesity treatment should not simply be losing weight.
It should be improving health.
How does it compare with semaglutide and tirzepatide?
This is where people should be cautious about making direct comparisons.
The numbers appear impressive:
Semaglutide: commonly produces roughly 15% average weight loss in obesity trials.
Tirzepatide: has produced average reductions around 20% or more at higher doses in major obesity trials.
Retatrutide: has now produced average reductions approaching 28% in Phase 3.
However, these numbers come from different trials involving different populations and study designs.
You cannot scientifically conclude that one medication is superior simply by placing results from separate studies next to one another.
Direct head-to-head trials are the better way to answer that question.
Those comparative studies are underway.
Still, the magnitude of weight loss seen with retatrutide makes it reasonable to expect that it could become a major obesity treatment if regulators ultimately approve it.
Is 30% weight loss always better?
Not necessarily.
This is an increasingly important question as obesity medications become more powerful.
Weight loss itself is not the only goal.
We also care about what kind of weight is being lost.
Large amounts of weight loss can include:
Fat mass
Visceral fat
Liver fat
Water
Lean body mass
Skeletal muscle
Losing excess fat is beneficial.
Losing excessive amounts of muscle is not.
This is particularly important in older adults, where maintaining muscle mass and strength is critical for:
Mobility
Balance
Glucose regulation
Bone health
Independence
Healthy aging
The more powerful these medications become, the more important nutrition and resistance training become.
Protecting muscle while losing weight
Anyone undergoing substantial medically assisted weight loss should pay attention to:
Protein intake
Adequate protein helps support preservation of lean tissue.
Resistance training
Strength training provides a signal to maintain muscle during a calorie deficit.
Adequate calories and micronutrients
Extreme appetite suppression can make it difficult to eat enough protein, vitamins, minerals, and fiber.
Rate of weight loss
Faster is not automatically better.
Body composition
In selected patients, measurements such as DEXA or other validated body-composition assessments may help distinguish fat loss from lean-mass loss.
A successful obesity treatment should ideally improve body composition and metabolic health rather than simply drive the lowest possible body weight.
What are the side effects?
Retatrutide appears to share many adverse effects with other incretin-based medications.
The most common are gastrointestinal:
Nausea
Vomiting
Diarrhea
Constipation
Reduced appetite
Abdominal discomfort
In the Phase 2 obesity trial, gastrointestinal effects were generally mild to moderate, were more common at higher doses, and were reduced somewhat by starting at a lower dose and gradually increasing it. (New England Journal of Medicine)
An increase in heart rate has also been observed.
In the Phase 2 trial, heart rate increased in a dose-dependent fashion, peaked around 24 weeks, and then declined. (New England Journal of Medicine)
Long-term cardiovascular and renal outcome studies remain important because producing dramatic weight loss does not automatically prove long-term cardiovascular safety or mortality benefit.
What about gallstones, pancreatitis, and other GLP-1 concerns?
If retatrutide is eventually approved, clinicians will likely need to consider many of the same issues that arise with current incretin therapies.
These can include:
Gallbladder disease
Pancreatitis concerns
Severe gastrointestinal symptoms
Dehydration
Kidney injury related to dehydration
Delayed gastric emptying
Nutrition deficiencies
Muscle loss
Medication interactions
Considerations before anesthesia or procedures
The final safety profile and prescribing information will ultimately depend on the completed Phase 3 program and regulatory review.
Will people need to take it forever?
Possibly.
One of the biggest misconceptions about obesity medications is that they permanently “cure” obesity after several months of treatment.
Obesity is often a chronic biologic disease.
When medications suppressing appetite and altering metabolic signaling are discontinued, hunger signals can return and weight regain is common with current GLP-1-based therapies.
There is no reason yet to assume retatrutide will be fundamentally different.
Long-term maintenance strategies will probably remain important.
Those strategies include:
Nutrition
Physical activity
Resistance training
Sleep
Stress management
Behavioral change
Long-term medication when appropriate
The medication can be a powerful tool.
It does not eliminate biology.
Retatrutide is not available yet
This point is particularly important.
Retatrutide is not currently FDA-approved.
Lilly states that the medication is available only through its clinical trials and specifically warns against products being sold online or through unauthorized clinics claiming to contain retatrutide. (Lilly)
Patients should be extremely cautious about buying products labeled:
“Research retatrutide”
“Compounded retatrutide”
“Triple agonist peptide”
“Not for human consumption”
An investigational molecule purchased from an unregulated source may contain the wrong concentration, contamination, impurities, or an entirely different substance.
The promising clinical trial data do not make gray-market versions of the drug safe.
Is retatrutide a longevity medication?
Not directly.
There is currently no evidence that retatrutide extends human lifespan.
However, severe obesity contributes to many diseases that shorten healthspan and lifespan, including:
Cardiovascular disease
Type 2 diabetes
Sleep apnea
Fatty liver disease
Kidney disease
Osteoarthritis
Several cancers
If a medication safely produces substantial and durable reductions in obesity and its complications, it could potentially have important long-term health implications.
But we need cardiovascular, kidney, cancer, functional, and mortality outcome data before calling it a longevity medication.
My practical take
Retatrutide may represent another major step forward in obesity medicine.
Semaglutide showed that targeting GLP-1 could produce meaningful weight loss.
Tirzepatide showed that combining GLP-1 with GIP could produce even greater results.
Retatrutide adds glucagon receptor activity and has now produced average weight reductions approaching 30% in some Phase 3 populations. (Eli Lilly and Company)
That is extraordinary.
But powerful medications require thoughtful use.
The goal should not simply be:
How much weight can we make someone lose?
The better questions are:
Are we improving metabolic health?
Are we preserving muscle and strength?
Are cardiovascular risk factors improving?
Can the patient maintain adequate nutrition?
Is the treatment sustainable and safe?
That is where obesity treatment and longevity medicine should intersect.
Bottom line
Retatrutide is an investigational once-weekly medication that activates GLP-1, GIP, and glucagon receptors.
That triple mechanism appears capable of producing exceptionally large reductions in body weight.
Phase 2 research showed approximately 24% average weight loss at 48 weeks, and Phase 3 results announced in 2026 showed approximately 28% average weight loss at 80 weeks at the highest dose, with some participants continuing toward 30% average loss with longer treatment. (New England Journal of Medicine)
It has also shown promising effects on diabetes, sleep apnea, knee osteoarthritis, and other obesity-related complications. (Eli Lilly and Company)
But retatrutide remains investigational and is not yet FDA-approved. Lilly currently expects to begin regulatory submissions in 2027. (Eli Lilly and Company)
If approved, it could become one of the most significant new treatments in obesity medicine.
But even as medications become more powerful, the foundations remain the same: nutrition, resistance training, cardiovascular fitness, sleep, behavior change, and long-term medical follow-up.